Inflammation in cystic fibrosis and its management

Paediatric Respiratory Reviews

Volumn 1, Issue 2, 2000, Pages 101-106

  Doring G ^a   Worlitzsch, D ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cytokines; Ibuprofen; Inflammation; Oxygen radicals; Steroids

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; NITRIC OXIDE;

ANIMAL; BACTERIAL INFECTION; CYSTIC FIBROSIS; HUMAN; IMMUNOLOGY; INFLAMMATION; NEUTROPHIL; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; CYTOKINES; HUMANS; INFLAMMATION; NEUTROPHILS; NITRIC OXIDE;

EID: 4444365750     PISSN: 15260550     EISSN: None     Source Type: Journal    
DOI: 10.1053/prrv.2000.0030     Document Type: Conference Paper

References (67)

1. Lloyd-Still JD. Pulmonary manifestations In: Lloyd-Still JD (ed). Textbook of Cystic Fibrosis. Boston: John Wright 1983; 165-198.
2. Döring G, Knight R, Bellon G. Immunology of cystic fibrosis. In: Hodson M E, Geddes D (eds). Cystic Fibrosis. London: Chapman and Hall 1995; 99-129.
3. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.
4. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995; 20: 63-70.
5. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1197-1204.
6. Zahm JM, Gaillard D, Dupuit F, Hinnrasky J, Porteous D, Dorin JR, Puchelle E. Early alterations in airway mucociliary clearance and inflammation of the lamina propria in CF mice. Am J Physiol 1997; 272: C853-C859.
7. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M. Inflammatory cytokines in cystic fibrosis lungs Am J Respir Crit Care Med 1995; 152: 2111-2118.
8. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is down-regulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995; 13: 257-261.
9. Woods DE, Strauss DC, Johanson WG Jr, Bass JA. The role of fibronectin in the prevention of adherence of Pseudomonas aeruginosa to buccal cells. J Infect Dis, 1981; 143: 784-790.
10. Plotkowski MC, Beck G, Tournier JM, Bernardo-Filho M, Marques EA, Puchelle E. Adherence of Pseudomonas aeruginosa to respiratory epithelium and the effect of leucocyte elastase.J Med Microbiol 1989; 30: 285-293.
11. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150: 448-454.
12. Ulrich M, Herbert S, Berger J, Bellon G, Louis D, Münker G, Döring G. Localization of Staphylococcus aureus in infected airways of patients with cystic fibrosis and in a cell culture model of S. aureus adherence. Am J Respir Crit Care Med 1998; 18: 1-9.
13. Worlitzsch D, Meyer KC, Birrer P, Döring G. Assessing oxygen: a bronchoscopic view into sputum-plugged cystic fibrosis airways. Pediatr Pulmonol 1998; suppl 17: A457, p 333.
14. Hassett DJ. Anaerobic production of alginate by Pseudomonas aeruginosa: alginate restricts diffusion of oxygen. J Bacterial 1996; 178: 7322-7325.
15. Mahenthiralingam E, Speert DP. Nonopsonic phagocytosis of Pseudomonas aeruginosa by macrophages and polymorphonuclear leukocytes requires the presence of the bacterial flagellum. Infect Immun 1995; 63: 4519-4523.
16. Learn DB, Brestel EP, Seethmarama S. Hypochlorite scavenging by Pseudomonas aeruginosa alginate. Infect Immun 1987; 55: 1813-1818.
17. Boucher JC, Yu H, Mudd MH, Deretic V. Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 1997; 65: 3838-3846.
18. 2 inhibition in vitro and in vivo. J Infect Dis 1997; 176: 431-438.
19. McKenney D, Tibbetts KL, Wang Y et al. Broadly-protective vaccine for Staphylococcus aureus based on an in vivo expressed antigen. Science 1999; 284: 1523-1527.
20. Döring G, Høiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun 1983; 42: 197-201.
21. Høiby N, Döring G, Schiøtz PO. The role of immune complexes in the pathogenesis of bacterial infections. Ann Rev Microbiol 1986; 40: 29-53.
22. Pressler T, Mansa B, Jensen T, Pedersen SS, Høiby N, Koch C. Increased IgG2 and IgG3 concentration is associated with advanced Pseudomonas aeruginosa infection and poor pulmonary function in cystic fibrosis. Acta Paediatr Scand 1988; 77: 576-582.
23. Thomassen MJ, Boxerbaum B, Demko CA, Kuchenbrod PJ, Dearborn DG, Wood RE. Inhibitory effect of cystic fibrosis serum on Pseudomonas phagocytosis by rabbit and human alveolar macrophages. Pediatr Res 1979; 13: 1085-1088.
24. Tosi MF, Zakem-Cloud H, Demko CA, Schreiber JR, Stern RC, Konstan MW, Berger M. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis 1995; 172, 453-461.
25. Goldstein W, Döring G. Lysosomal enzymes and proteinase inhibitors in the sputum of patients with cystic fibrosis. Am Rev Respir Dis 1986; 134: 49-56.
26. Vogelmeier C, Hubbard RC, Fells GA, Schnebli H-P, Thompson RC, Fritz H, Crystal RG. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 1991; 87: 482-488.
27. Schuster A, Csemok E, Johnston TW, Groß W. Proteinase-3 in cystic fibrosis airways. Am J Respir Crit Care Med 1997; 155: A49.
28. Stone P, Konstan MH, Berger M, Dorkin HL, Franzblau C, Snider GL. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med 1995; 152: 157-162.
29. Döring G, Goldstein W, Botzenhart K, Kharazmi A, Schiøtz PO, Høiby N, Dasgupta M. Elastase from polymorphonuclear leucocytes - a regulatory enzyme in immune complex disease. Clin Exp Immunol 1986; 64: 597-605.
30. Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonized Pseudomonas as well as CRI on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 1990; 86: 300-308.
31. Berger M, Sorensen RU, Tosi MF, Dearborn DG, Döring G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989; 84: 1302-1313.
32. Döring G, Frank F, Boudier C, Herbert S, Fleischer B, Bellon G. Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. J Immunol 1995; 154: 4842-4850.
33. Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990; 85: 682-689.
34. Koller DY, Urbanek R, Götz M. Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis. AmJ Respir Crit Care Med 1995; 152: 629-633.
35. Portal BC, Richard MJ, Faure HS, Hadjian AJ, Favier AE. Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis. Am J Clin Nutr 1995; 61: 843-847.
36. Langley SC, Brown RK, Kelly FJ. Reduced free-radical-trapping capacity and altered plasma antioxidant status in cystic fibrosis. Pediatr Res 1993; 33: 247-250.
37. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993; 75: 2419-2424.
38. Worlitzsch D, Herberth G, Ulrich M, Döring G. Catalase, myeloperoxidase and hydrogen peroxide in cystic fibrosis. Eur Respir J 1998; 11: 377-383.
39. Moldawer LL, Lowry SF. Cachectin: its impact on metabolism and nutritional status. Ann Rev Nutr 1988; 8: 585-609.
40. Teramoto S, Matsuse T, Ouchi Y. Increased production of TNF-alpha may play a role in osteoporosis in cystic fibrosis patients. Chest 1997; 112: 574.
41. Nakamura H, Yoshimura K, McElvaney, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992; 89: 1478-1484.
42. Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna, M, Wei T, Gardner P. Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin Exp Immunol 1996; 106: 374-388.
43. Moncada S, Higgs EA. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest 1991; 21: 361-374.
44. Grasemann H, Michler E, Wallot M, Ratjen F. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 1997; 24: 173-177.
45. Meng Q-H, Springall DR, Bishop AE et al. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 1998; 184: 323-331.
46. Auerbach HS, Williams M, Kirkpatrick JA, Colton HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2: 686-688.
47. Rosenstein BJ, Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 1990; 87: 245-246.
48. van Haren EH, Lammers JW, Festen J, Heijerman HG, Groot CA, van Herwaarden CL. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 1995; 89: 209-214.
49. Nikolaizik WH, Schöni MH. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 1996; 128: 271-274.
50. Balfour-Lynn IM, Klein NJ, Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997; 77: 124-130.
51. Bisgaard H, Pedersen SS, Nielsen KG, Skov M, Laursen EM, Kronborg G, Reimert CM, Høiby N, Koch C. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997; 156: 1190-1196.
52. Greally P, Hussain MJ, Vergani D, Price JF. Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child 1994; 71: 35-39.
53. Sordelli DO, Macri CN, Maille AJ, Cerquetti MC. A preliminary study on the effect of anti-inflammatory treatment in cystic fibrosis patients with Pseudomonas aeruginosa lung infection. Int J Immunopathol Pharmacol 1994; 7: 109-117.
54. Aronoff SC, Quinn FJ Jr, Carpenter LS, Novick WJ Jr. Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations. J Pediatr 1994; 125: 992-997.
55. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-854.
56. Konstan MW, Hoppel CL, Chai B-L, Davis PB. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr 1991; 118: 956-964.
57. Lloyd-Still JD, Bibus DM, Powers CA, Johnson SB, Holman RT. Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatr 1996; 85: 1426-1432.
58. Henderson WR Jr, Astley SJ, McCready MM, Kushmerick P, Casey S, Becker JW, Ramsey BW Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J Pediatr 1994; 124: 400-408.
59. Ghio AJ, Marshall BC, Diaz JL, Hasegawa T, Samuelson W, Povia D, Kennedy TP, Piantodosi CA. Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCl, and reduces viscosity of cystic fibrosis sputum. Am J Respir Crit Care Med 1996; 154: 783-788.
60. Pierangeli SS, Polk HC Jr, Parmely MJ, Sonnenfeld G. Murine interferon-gamma enhances resistance to infection with strains of Pseudomonas aeruginosa in mice. Cytokine 1993; 5: 230-234.
61. Johansen HK, Hougen HP, Rygaard J, Høiby, N. Interferon-gamma (IFN-gamma) treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats. Clin Exp Immunol 1996; 103: 212-218.
62. 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-394.
63. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, Crystal RG. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992; 90: 1296-1301.
64. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993; 148: 1056-1060.
65. Mumford RA, Chabin R, Chiu S et al. A cell-penetrant monocyclic β-lactam inhibitor (MBI) which inactivates elastase within PMN in vitro and in vivo. Am J Respir Crit Care Med 1995; 151: A532.
66. 1-antitrypsin (tg-hAAT) as an effective treatment of cystic fibrosis.
67. Cantin AM, Woods DE. Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med 1999; 160: 1130-1135.